Insulin-like growth factors and breast cancer therapy

Advances in Experimental Medicine and Biology

Volumn 608, Issue , 2007, Pages 101-112

  Zeng, Xianke ^a   Yee, Douglas ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; SOMATOMEDIN; SOMATOMEDIN RECEPTOR;

BREAST TUMOR; DRUG ANTAGONISM; FEMALE; HUMAN; METABOLISM; REVIEW;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; RECEPTORS, SOMATOMEDIN; SOMATOMEDINS;

EID: 38449090883     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-0-387-74039-3_7     Document Type: Review

References (106)

1. Jemal A, Tiwari RC, Murray T et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54(1):8-29.
2. Polychemotherapy for early breast cancer: An overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998;352(9132):930-942.
3. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344(11):783-792.
4. Yee D. The insulin-like growth factors and breast cancer-revisited. Breast Cancer Res Treat 1998;47(3):197-199.
5. Papa V, Gliozzo B, Clark GM et al. Insulin-like growth factor-I receptors are overexpressed and predict a low risk in human breast cancer. Cancer Res 1993;53(16):3736-3740.
6. Resnik JL, Reichart DB, Huey K et al. Elevated insulin-like growth factor I receptor autophosphorylation and kinase activity in human breast cancer. Cancer Res 1998;58(6):1159-1164.
7. Li BD, Khosravi MJ, Berkel HJ et al. Free insulin-like growth factor-I and breast cancer risk. Int J Cancer 2001;91(5):736-739.
8. Michels KB, Willett WC. Breast cancer-early life matters. N Engl J Med 2004;351(16):1679-1681.
9. Lu Y, Zi X, Zhao Y et al. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 2001;93(24):1852-1857.
10. Wen B, Deutsch E, Marangoni E et al. Tyrphostin AG 1024 modulates radiosensitivity in human breast cancer cells. Br J Cancer 2001;85(12):2017- 2021.
11. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004;4(7):505-518.
12. Sachdev D, Yee D. The IGF system and breast cancer. Endocr Relat Cancer 2001;8(3):197-209.
13. Moschos SJ, Mantzoros CS. The role of the IGF system in cancer: From basic to clinical studies and clinical applications. Oncology 2002;63(4):317-332.
14. Laban C, Bustin SA, Jenkins PJ. The GH-IGF-I axis and breast cancer. Trends Endocrinol Metab 2003;14(1):28-34.
15. Baker J, Liu JP, Robertson EJ et al. Role of insulin-like growth factors in embryonic and postnatal growth. Cell 1993;75(1):73-82.
16. DeChiara TM, Efstratiadis A, Robertson EJ. A growth-deficiency phenotype in heterozygous mice carrying an insulin-like growth factor II gene disrupted by targeting. Natur 1990;345(6270):78-80.
17. Ahlgren M, Melbye M, Wohlfahrt J et al. Growth patterns and the risk of breast cancer in women. N Engl J Med 2004;351(16):1619-1626.
18. Kim HS, Ingermann AR, Tsubaki J et al. Insulin-like growth factor-binding protein 3 induces caspase-dependent apoptosis through a death receptor-mediated pathway in MCF-7 human breast cancer cells. Cancer Res 2004;64(6):2229-2237.
19. Pandini G, Frasca F, Mineo R et al. Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved. J Biol Chem 2002;277(42):39684-39695.
20. Pandini G, Vigneri R, Costantino A et al. Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: Evidence for a second mechanism of IGF-I signaling. Clin Cancer Res 1999;5(7):1935-1944.
21. Zhang X, Yee D. Tyrosine kinase signalling in breast cancer: Insulin-like growth factors and their receptors in breast cancer. Breast Cancer Res 2000;2(3):170-175.
22. Ahmad S, Singh N, Glazer RI. Role of AKT1 in 17beta-estradiol-and insulin-like growth factor I (IGF-I)-dependent proliferation and prevention of apoptosis in MCF-7 breast carcinoma cells. Biochem Pharmacol 1999;58(3):425-430.
23. Hankins GR, Desouza AT, Bentley RC et al. M6P/IGF2 receptor: A candidate breast tumor suppressor gene. Oncogene 1996;12(9):2003-2009.
24. Marshman E, Green KA, Flint DJ et al. Insulin-like growth factor binding protein 5 and apoptosis in mammary epithelial cells. J Cell Sci 2003;116(Pt 4):675-682.
25. Deeks S, Richards J, Nandi S. Maintenance of normal rat mammary epithelial cells by insulin and insulin-like growth factor 1. Exp Cell Res 1988;174(2):448-460.
26. Richert MM, Wood TL. The insulin-like growth factors (IGF) and IGF type I receptor during postnatal growth of the murine mammary gland: Sites of messenger ribonucleic acid expression and potential functions. Endocrinology 1999;140(1):454-461.
27. Ruan W, Kleinberg DL. Insulin-like growth factor I is essential for terminal end bud formation and ductal morphogenesis during mammary development. Endocrinology 1999;140(11):5075-5081.
28. Hadsell DL, Greenberg NM, Fligger JM et al. Targeted expression of des (1-3) human insulin-like growth factor I in transgenic mice influences mammary gland development and IGF-binding protein expression. Endocrinology 1996;137(1):321-330.
29. Hadsell DL, Bonnette SG, Lee AV. Genetic manipulation of the IGF-I axis to regulate mammary gland development and function. J Dairy Sci 2002;85(2):365-377.
30. Gilmore AP, Valentijn AJ, Wang P et al. Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptor. J Biol Chem 2002;277(31):27643-27650.
31. Marshman E, Streuli CH. Insulin-like growth factors and insulin-like growth factor binding proteins in mammary gland function. Breast Cancer Res 2002;4(6):231-239.
32. Tonner E, Barber MC, Allan GJ et al. Insulin-like growth factor binding protein-5 (IGFBP-5) induces premature cell death in the mammary glands of transgenic mice. Development 2002;129(19):4547-4557.
33. Toniolo P, Bruning PF, Akhmedkhanov A et al. Serum insulin-like growth factor-I and breast cancer. Int J Cancer 2000;88(5):828-832.
34. Paik S. Expression of IGF-I and IGF-II mRNA in breast tissue. Breast Cancer Res Treat 1992;22(1):31-38.
35. Ruan W, Newman CB, Kleinberg DL. Intact and amino-terminally shortened forms of insulin-like growth factor I induce mammary gland differentiation and development. Proc Natl Acad Sci USA 1992;89(22):10872-10876.
36. Ruan W, Catanese V, Wieczorek R et al. Estradiol enhances the stimulatory effect of insulin-like growth factor-I (IGF-I) on mammary development and growth hormone-induced IGF-I messenger ribonucleic acid. Endocrinology 1995;136(3):1296-1302.
37. Wu Y, Cui K, Miyoshi K et al. Reduced circulating insulin-like growth factor I levels delay the onset of chemically and genetically induced mammary tumors. Cancer Res 2003;63(15):4384-4388.
38. Hankinson SE, Willett WC, Colditz GA et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998;351(9113):1393-1396.
39. Cullen KJ, Yee D, Sly WS et al. Insulin-like growth factor receptor expression and function in human breast cancer. Cancer Res 1990;50(1):48-53.
40. Pezzino V, Papa V, Milazzo G et al. Insulin-like growth factor-I (IGF-I) receptors in breast cancer. Ann NY Acad Sci 1996;784:189-201.
41. Turner BC, Haffty BG, Narayanan L et al. Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Res 1997;57(15):3079-3083.
42. Rocha RL, Hilsenbeck SG, Jackson JG et al. Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: Correlation with clinical parameters and disease-free survival. Clin Cancer Res 1997;3(1):103-109.
43. Lee AV, Jackson JG, Gooch JL et al. Enhancement of insulin-like growth factor signaling in human breast cancer: Estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. Mol Endocrinol 1999;13(5):787-796.
44. Hoang CD, Zhang X, Scott PD et al. Selective activation of insulin receptor substrate-1 and-2 in pleural mesothelioma cells: Association with distinct malignant phenotypes. Cancer Res 2004;64(20):7479-7485.
45. Zhang X, Kamaraju S, Hakuno F et al. Motility response to insulin-like growth factor-I (IGF-I) in MCF-7 cells is associated with IRS-2 activation and integrin expression. Breast Cancer Res Treat 2004;83(2):161-170.
46. Nagle JA, Ma Z, Byrne MA et al. Involvement of insulin receptor substrate 2 in mammary tumor metastasis. Mol Cell Biol 2004;24(22):9726-9735.
47. Perks CM, Bowen S, Gill ZP et al. Differential IGF-independent effects of insulin-like growth factor binding proteins (1-6) on apoptosis of breast epithelial cells. J Cell Biochem 1999;75(4):652-664.
48. Oh Y, Muller HL, Lamson G et al. Insulin-like growth factor (IGF)-independent action of IGF-binding protein-3 in Hs578T human breast cancer cells. Cell surface binding and growth inhibition. J Biol Chem 1993;268(20):14964-14971.
49. Al-Hajj M, Wicha MS, Benito-Hernandez A et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003;100(7):3983- 3988.
50. Baselga J, Norton L. Focus on breast cancer. Cancer Cell 2002;1(4):319-322.
51. Tamoxifen for early breast cancer: An overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998;351(9114):1451- 1467.
52. Rubin R, Baserga R. Insulin-like growth factor-I receptor. Its role in cell proliferation, apoptosis, and tumorigenicity. Lab Invest 1995;73(3):311-331.
53. Gooch JL, Van Den Berg CL, Yee D. Insulin-like growth factor (IGF)-I rescues breast cancer cells from chemotherapy-induced cell death-proliferative and anti-apoptotic effects. Breast Cancer Res Treat 1999;56(1):1-10.
54. Xie SP, Pirianov G, Colston KW. Vitamin D analogues suppress IGF-I signalling and promote apoptosis in breast cancer cells. Eur J Cancer 1999;35(12):1717-1723.
55. Kulik G, Klippel A, Weber MJ. Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt. Mol Cell Biol 1997;17(3):1595-1606.
56. Kothari S, Cizeau J, McMillan-Ward E et al. BNIP3 plays a role in hypoxic cell death in human epithelial cells that is inhibited by growth factors EGF and IGF. Oncogene 2003;22(30):4734-4744.
57. Peruzzi F, Prisco M, Dews M et al. Multiple signaling pathways of the insulin-like growth factor 1 receptor in protection from apoptosis. Mol Cell Biol 1999;19(10):7203-7215.
58. Zha J, Harada H, Yang E et al. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X (L). Cell 1996;87(4):619-628.
59. Singleton JR, Dixit VM, Feldman EL. Type I insulin-like growth factor receptor activation regulates apoptotic proteins. J Biol Chem 1996;271(50):31791-31794.
60. Dunn SE, Hardman RA, Kari FW et al. Insulin-like growth factor 1 (IGF-1) alters drug sensitivity of HBL100 human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs. Cancer Res 1997;57(13):2687-2693.
61. Lu Y, Zi X, Pollak M. Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells. Int J Cancer 2004;108(3):334-341.
62. Mamay CL, Mingo-Sion AM, Wolf DM et al. An inhibitory function for JNK in the regulation of IGF-I signaling in breast cancer. Oncogene 2003;22(4):602-614.
63. Heron-Milhavet L, Karas M, Goldsmith CM et al. Insulin-like growth factor-I (IGF-I) receptor activation rescues UV-damaged cells through a p38 signaling pathway. Potential role of the IGF-I receptor in DNA repair. J Biol Chem 2001;276(21):18185-18192.
64. Heron-Milhavet L, LeRoith D. Insulin-like growth factor I induces MDM2-dependent degradation of p53 via the p38 MAPK pathway in response to DNA damage. J Biol Chem 2002;277(18):15600-15606.
65. Shahrabani-Gargir L, Pandita TK, Werner H. Ataxia-telangiectasia mutated gene controls insulin-like growth factor I receptor gene expression in a deoxyribonucleic acid damage response pathway via mechanisms involving zinc-finger transcription factors Sp1 and WT1. Endocrinology 2004;145(12):5679-5687.
66. Kuhn C, Hurwitz SA, Kumar MG et al. Activation of the insulin-like growth factor-1 receptor promotes the survival of human keratinocytes following ultraviolet B irradiation. Int J Cancer 1999;80(3):431-438.
67. Decraene D, Agostinis P, Bouillon R et al. Insulin-like growth factor-1-mediated AKT activation postpones the onset of ultraviolet B-induced apoptosis, providing more time for cyclobutane thymine dimer removal in primary human keratinocytes. J Biol Chem 2002;277(36):32587-32595.
68. Trojanek J, Ho T, Del Valle L et al. Role of the insulin-like growth factor I/insulin receptor substrate 1 axis in Rad51 trafficking and DNA repair by homologous recombination. Mol Cell Biol 2003;23(21):7510-7524.
69. Jayanth VR, Belfi CA, Swick AR et al. Insulin and insulin-like growth factor-1 (IGF-1) inhibit repair of potentially lethal radiation damage and chromosome aberrations and alter DNA repair kinetics in plateau-phase A549 cells. Radiat Res 1995;143(2):165-174.
70. Holdaway IM, Mason BH, Lethaby AE et al. Serum insulin-like growth factor-I and insulin-like growth factor binding protein-3 following chemotherapy for advanced breast cancer. ANZ J Surg 2003;73(11):905-908.
71. Kajdaniuk D, Marek B. Influence of adjuvant chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil on plasma insulin-like growth factor-I and chosen hormones in breast cancer premenopausal patients. J Clin Pharm Ther 2000;25(1):67-72.
72. Formelli F. Quality control for HPLC assay and surrogate end point biomarkers from the fenretinide (4-HPR) breast cancer prevention trial. J Cell Biochem Suppl 2000;34:73-79.
73. Yang LM, Tin UC, Wu K et al. Role of retinoid receptors in the prevention and treatment of breast cancer. J Mammary Gland Biol Neoplasia 1999;4(4):377-388.
74. Chrzanowski K, Bielawska A, Palka J. Proline analogue of melphalan as a prodrug susceptible to the action of prolidase in breast cancer MDA-MB 231 cells. Farmaco 2003;58(11):1113-1119.
75. Gronbaek H, Tanos V, Meirow D et al. Effects of tamoxifen on insulin-like growth factors, IGF binding proteins and IGFBP-3 proteolysis in breast cancer patients. Anticancer Res 2003;23(3C): 2815-2820.
76. Ferrari L, Bajetta E, Martinetti A et al. Could exemestane affect insulin-like growth factors, interleukin 6 and bone metabolism in postmenopausal advanced breast cancer patients after failure on aminoglutethimide, anastrozole or letrozole? Int J Oncol 2003;22(5):1081-1089.
77. Torrisi R, Baglietto L, Johansson H et al. Effect of raloxifene on IGF-I and IGFBP-3 in postmenopausal women with breast cancer. Br J Cancer 2001;85(12):1838-1841.
78. Nielsen TO, Andrews HN, Cheang M et al. Expression of the insulin-like growth factor I receptor and urokinase plasminogen activator in breast cancer is associated with poor survival: Potential for intervention with 17-allylamino geldanamycin. Cancer Res 2004;64(1):286-291.
79. Jerome L, Shiry L, Leyland-Jones B. Anti-insulin-like growth factor strategies in breast cancer. Semin Oncol 2004;31(1 Suppl 3):54-63.
80. Byron SA, Yee D. Potential therapeutic strategies to interrupt insulin-like growth factor signaling in breast cancer. Semin Oncol 2003;30(5 Suppl 16):125-132.
81. Szepeshazi K, Schally AV, Armatis P et al. Antagonists of GHRH decrease production of GH and IGF-I in MXT mouse mammary cancers and inhibit tumor growth. Endocrinology 2001;142(10):4371-4378.
82. Kahan Z, Varga JL, Schally AV et al. Antagonists of growth hormone-releasing hormone arrest the growth of MDA-MB-468 estrogen-independent human breast cancers in nude mice. Breast Cancer Res Treat 2000;60(1):71-79.
83. Ingle JN, Suman VJ, Kardinal CG et al. A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinoma. Cancer 1999;85(6):1284-1292.
84. Friend KE. Cancer and the potential place for growth hormone receptor antagonist therapy. Growth Horm IGF Res 2001;11(Suppl A): S121-123.
85. Van den Berg CL, Cox GN, Stroh CA et al. Polyethylene glycol conjugated insulin-like growth factor binding protein-1 (IGFBP-1) inhibits growth of breast cancer in athymic mice. Eur J Cancer 1997;33(7):1108-1113.
86. Yee D, Jackson JG, Kozelsky TW et al. Insulin-like growth factor binding protein-1 (IGFBP-1) expression inhibits IGF-I action in MCF-7 breast cancer cells. Cell Growth and Differentiation 1994;5:73-77.
87. Zi X, Zhang J, Agarwal R et al. Silibinin up-regulates insulin-like growth factor-binding protein 3 expression and inhibits proliferation of androgen-independent prostate cancer cells. Cancer Res 2000;60(20):5617-5620.
88. D'Ambrosio C, Ferber A, Resnicoff M et al. A soluble insulin-like growth factor I receptor that induces apoptosis of tumor cells in vivo and inhibits tumorigenesis. Cancer Res 1996;56(17):4013-4020.
89. Samani AA, Chevet E, Fallavollita L et al. Loss of tumorigenicity and metastatic potential in carcinoma cells expressing the extracellular domain of the type 1 insulin-like growth factor receptor. Cancer Res 2004;64(10):3380- 3385.
90. Goya M, Miyamoto S, Nagai K et al. Growth inhibition of human prostate cancer cells in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice by a ligand-specific antibody to human insulin-like growth factors. Cancer Res 2004;64(17):6252-6258.
91. Arteaga CL, Kitten LJ, Coronado EB et al. Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J Clin Invest 1989;84(5):1418-1423.
92. Li SL, Liang SJ, Guo N et al. Single-chain antibodies against human insulin-like growth factor I receptor: Expression, purification, and effect on tumor growth. Cancer Immunol Immunother 2000;49(4-5): 243-252.
93. Sachdev D, Li SL, Hartell JS et al. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I. Cancer Res 2003;63(3):627-635.
94. Ye JJ, Liang SJ, Guo N et al. Combined effects of tamoxifen and a chimeric humanized single chain antibody against the type I IGF receptor on breast tumor growth in vivo. Horm Metab Res 2003;35(11-12): 836-842.
95. Maloney EK, McLaughlin JL, Dagdigian NE et al. An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res 2003;63(16):5073-5083.
96. Burtrum D, Zhu Z, Lu D et al. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res 2003;63(24):8912-8921.
97. Blum G, Gazit A, Levitzki A. Development of new insulin-like growth factor-1 receptor kinase inhibitors using catechol mimics. J Biol Chem 2003;278(42):40442-40454.
98. Parrizas M, Gazit A, Levitzki A et al. Specific inhibition of insulin-like growth factor-1 and insulin receptor tyrosine kinase activity and biological function by tyrphostins. Endocrinology 1997;138(4):1427-1433.
99. Mitsiades CS, Mitsiades NS, McMullan CJ et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 2004;5(3):221-230.
100. Garcia-Echeverria C, Pearson MA, Marti A et al. In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell 2004;5(3):231-239.
101. Salatino M, Schillaci R, Proietti CJ et al. Inhibition of in vivo breast cancer growth by antisense oligodeoxynucleotides to type I insulin-like growth factor receptor mRNA involves inactivation of ErbBs, PI-3K/Akt and p42/p44 MAPK signaling pathways but not modulation of progesterone receptor activity. Oncogene 2004;23(30):5161-5174.
102. Beech DJ, Parekh N, Pang Y. Insulin-like growth factor-I receptor antagonism results in increased cytotoxicity of breast cancer cells to doxorubicin and taxol. Oncol Rep 2001;8(2):325-329.
103. Benini S, Manara MC, Baldini N et al. Inhibition of insulin-like growth factor I receptor increases the antitumor activity of doxorubicin and vincristine against Ewing's sarcoma cells. Clin Cancer Res 2001;7(6):1790-1797.
104. Camirand A, Pollak M. Cotargeting IGF-1R and c-kit: Synergistic inhibition of proliferation and induction of apoptosis in H 209 small cell lung cancer cells. Br J Cancer 2004;90(9):1825-1829.
105. Baserga R. Targeting the IGF-1 receptor: From rags to riches. Eur J Cancer 2004;40(14):2013-2015.
106. Albain KS, Green SJ, Ravdin PM et al. Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: Initial results from intergroup trial 0100 (SWOG-8814). Proc ASCO 2002, (Abs#:143).